Brokerages Set TScan Therapeutics, Inc. (NASDAQ:TCRX) Target Price at $9.33

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have been given an average recommendation of “Buy” by the six analysts that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have covered the stock in the last year is $9.33.

A number of research analysts recently commented on the company. Needham & Company LLC decreased their price target on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, March 5th. Wedbush reissued an “outperform” rating and issued a $7.00 target price on shares of TScan Therapeutics in a report on Wednesday, March 5th. Morgan Stanley reaffirmed an “overweight” rating and set a $10.00 price target on shares of TScan Therapeutics in a report on Friday, March 14th. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a research report on Thursday, March 6th. Finally, Barclays lowered their price objective on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a research report on Friday, March 7th.

TScan Therapeutics Stock Up 2.6 %

NASDAQ TCRX opened at $1.59 on Friday. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. The company has a market cap of $89.98 million, a price-to-earnings ratio of -1.50 and a beta of 0.91. The company has a 50 day moving average of $2.23 and a 200-day moving average of $3.80. TScan Therapeutics has a 1-year low of $1.51 and a 1-year high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). The company had revenue of $0.67 million for the quarter, compared to the consensus estimate of $1.43 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. On average, equities research analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TScan Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. acquired a new position in TScan Therapeutics during the 4th quarter worth approximately $32,000. Prudential Financial Inc. acquired a new position in shares of TScan Therapeutics during the fourth quarter worth $32,000. ProShare Advisors LLC acquired a new position in shares of TScan Therapeutics during the fourth quarter worth $40,000. Squarepoint Ops LLC bought a new position in shares of TScan Therapeutics in the 4th quarter valued at $59,000. Finally, Wells Fargo & Company MN boosted its holdings in shares of TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock valued at $59,000 after acquiring an additional 5,694 shares in the last quarter. 82.83% of the stock is currently owned by institutional investors and hedge funds.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.